Halozyme Therapeutics Inc’s recently made public that its Director Connaughton Bernadette unloaded Company’s shares for reported $59356.0 on Dec 01 ’25. In the deal valued at $71.60 per share,829 shares were sold. As a result of this transaction, Connaughton Bernadette now holds 42,123 shares worth roughly $2.67 million.
Then, Torley Helen sold 16,569 shares, generating $1,141,925 in total proceeds. Upon selling the shares at $68.92, the PRESIDENT AND CEO now owns 708,719 shares.
Before that, Torley Helen sold 20,000 shares. Halozyme Therapeutics Inc shares valued at $1,410,990 were divested by the PRESIDENT AND CEO at a price of $70.55 per share. As a result of the transaction, Torley Helen now holds 733,719 shares, worth roughly $46.47 million.
Goldman downgraded its Halozyme Therapeutics Inc [HALO] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in mid October from “an Underperform” to “a Market perform”. Morgan Stanley also remained covering HALO and has increased its forecast on August 06, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating.
Price Performance Review of HALO
On Friday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock jump 0.60% to $63.33. Over the last five days, the stock has lost -11.30%. Halozyme Therapeutics Inc shares have risen nearly 30.63% since the year began. Nevertheless, the stocks have risen 32.46% over the past one year. While a 52-week high of $79.50 was reached on 09/23/25, a 52-week low of $46.26 was recorded on 05/14/25.
Levels Of Support And Resistance For HALO Stock
The 24-hour chart illustrates a support level at 62.62, which if violated will result in even more drops to 61.91. On the upside, there is a resistance level at 64.01. A further resistance level may holdings at 64.69.
How much short interest is there in Halozyme Therapeutics Inc?
A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2025-11-14, growing by 0.97 million shares to a total of 12.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 11.51 million shares. There was a rise of 7.77%, which implies that there is a positive sentiment for the stock.
